What is ThinkGenetic?
ThinkGenetic, established in 2015 and headquartered in Virginia, United States, is at the forefront of leveraging artificial intelligence (AI) to identify individuals with diagnosed and undiagnosed genetic diseases. The company's sophisticated AI solutions aim to bridge critical gaps in genetic diagnostics, offering a powerful tool for both healthcare providers and patients seeking clarity on complex genetic conditions. Its market position is defined by its specialized focus on AI-driven genetic analysis, a rapidly evolving and high-impact area within health tech.
How much funding has ThinkGenetic raised?
ThinkGenetic has raised a total of $2M across 2 funding rounds:
Other Financing Round
$1.5M
Other Financing Round
$500K
Other Financing Round (2019): $1.5M, investors not publicly disclosed
Other Financing Round (2021): $500K led by Ochsner Lafayette General Healthcare Innovation Fund
Key Investors in ThinkGenetic
Ochsner Lafayette General Healthcare Innovation Fund
Ochsner Lafayette General Healthcare Innovation Fund is likely a venture capital arm focused on investing in innovative healthcare solutions and technologies that can enhance patient care and operational efficiency within the healthcare system.
What's next for ThinkGenetic?
With substantial enterprise-level backing and a recent strategic investment, ThinkGenetic is poised for accelerated expansion and further development of its AI diagnostic capabilities. The company's trajectory suggests a focus on scaling its operations, enhancing its technological infrastructure, and potentially forging new strategic partnerships within the healthcare ecosystem. Future endeavors will likely involve broadening the reach of its diagnostic tools and solidifying its leadership in the AI-powered genetic disease identification market. This capital infusion is expected to fuel innovation and market penetration, reinforcing ThinkGenetic's role in advancing precision medicine.
See full ThinkGenetic company page
